Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trialMwayiwawo Madanitsa, Feiko O. ter Kuile, Kamija S. Phiri et al.|The Lancet|2023Cited by 72
Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin–piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trialHellen C. Barsosio, Feiko O. ter Kuile, Mwayiwawo Madanitsa et al.|The Lancet|2024Cited by 21
Performance of a rapid antigen test for SARS-CoV-2 in KenyaSimon Onsongo, Tobias F. Rinke de Wit, Kephas Otieno et al.|Diagnostic Microbiology and Infectious Disease|2021Cited by 20
Dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a systematic review and individual participant data meta-analysisMichelle E. Roh, Feiko O. ter Kuile, Julie Gutman et al.|EClinicalMedicine|2025Cited by 17
Public-private partnership to rapidly strengthen and scale COVID-19 response in Western KenyaShannen van Duijn, Tobias F. Rinke de Wit, Hellen C. Barsosio et al.|Frontiers in Public Health|2023Cited by 10